Scientific publications
Authors' Response
Mateos MV(1), Shi H(2), San Miguel JF(3).
(1) Hospital Universitario Salamanca, Instituto Biosanitario de Salamanca (IBSAL), Spain.
(2) Takeda Pharmaceuticals International Co., Cambridge, MA, USA.
(3) Clinica Universidad de Navarra, Centro Investigación Medica Aplicada, Pamplona, Spain.
Comment on
Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study. [Am J Hematol. 2015]
Immortal time bias and reverse causality in retrospective analysis: Comment on "effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study". [Am J Hematol. 2015]
CITATION Am J Hematol. 2015 Aug;90(8):E146. doi: 10.1002/ajh.24079.
Our authors
